MIF activates the MEK/ERK pathway [58] to promote tumor cell proliferation, survival and metastasis in a dose-dependent manner by downregulating p53 [33] and upregulating BCL2 and CD74 [57]. This evidence concerns the gene CD74 and neoplasm.